CN115957178A - External anti-inflammatory and bacteriostatic gel spray and preparation method thereof - Google Patents
External anti-inflammatory and bacteriostatic gel spray and preparation method thereof Download PDFInfo
- Publication number
- CN115957178A CN115957178A CN202211331456.7A CN202211331456A CN115957178A CN 115957178 A CN115957178 A CN 115957178A CN 202211331456 A CN202211331456 A CN 202211331456A CN 115957178 A CN115957178 A CN 115957178A
- Authority
- CN
- China
- Prior art keywords
- egcg
- solution
- pll
- sodium hyaluronate
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 41
- 239000007921 spray Substances 0.000 title claims abstract description 32
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract description 11
- 230000003385 bacteriostatic effect Effects 0.000 title abstract description 9
- 239000000499 gel Substances 0.000 claims abstract description 50
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 43
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 43
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 43
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims abstract description 42
- 239000000017 hydrogel Substances 0.000 claims abstract description 35
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims abstract description 30
- 108010039918 Polylysine Proteins 0.000 claims abstract description 27
- 102000003425 Tyrosinase Human genes 0.000 claims abstract description 27
- 108060008724 Tyrosinase Proteins 0.000 claims abstract description 27
- 229920000656 polylysine Polymers 0.000 claims abstract description 27
- 239000002253 acid Substances 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims abstract description 7
- 150000004676 glycans Chemical class 0.000 claims abstract description 6
- 230000003197 catalytic effect Effects 0.000 claims abstract description 4
- 238000009833 condensation Methods 0.000 claims abstract description 4
- 230000005494 condensation Effects 0.000 claims abstract description 4
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 4
- 239000005017 polysaccharide Substances 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 87
- 239000007864 aqueous solution Substances 0.000 claims description 35
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 32
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 28
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 28
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 28
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 16
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 16
- 238000005303 weighing Methods 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 13
- 238000000502 dialysis Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 238000004108 freeze drying Methods 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 230000008878 coupling Effects 0.000 claims description 8
- 238000010168 coupling process Methods 0.000 claims description 8
- 238000005859 coupling reaction Methods 0.000 claims description 8
- HJKLEAOXCZIMPI-UHFFFAOYSA-N 2,2-diethoxyethanamine Chemical compound CCOC(CN)OCC HJKLEAOXCZIMPI-UHFFFAOYSA-N 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 238000002390 rotary evaporation Methods 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000035484 reaction time Effects 0.000 claims 1
- 229940030275 epigallocatechin gallate Drugs 0.000 abstract description 25
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 abstract description 22
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 8
- 230000003647 oxidation Effects 0.000 abstract description 6
- 238000007254 oxidation reaction Methods 0.000 abstract description 6
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 abstract description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 5
- 230000004962 physiological condition Effects 0.000 abstract description 4
- 229940079877 pyrogallol Drugs 0.000 abstract description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 abstract description 2
- 238000007112 amidation reaction Methods 0.000 abstract description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 abstract description 2
- 235000005487 catechin Nutrition 0.000 abstract description 2
- 229950001002 cianidanol Drugs 0.000 abstract description 2
- 230000001404 mediated effect Effects 0.000 abstract description 2
- 150000004804 polysaccharides Polymers 0.000 abstract description 2
- 208000027418 Wounds and injury Diseases 0.000 description 17
- 206010052428 Wound Diseases 0.000 description 15
- 230000000844 anti-bacterial effect Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 12
- 230000029663 wound healing Effects 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 7
- 230000003213 activating effect Effects 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 208000035874 Excoriation Diseases 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000034656 Contusions Diseases 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 230000003670 easy-to-clean Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000011056 performance test Methods 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000001266 bandaging Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- LGLFFNDHMLKUMI-UHFFFAOYSA-N crystal violet cation Chemical compound C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)N(C)C)=C1C=CC(=[N+](C)C)C=C1 LGLFFNDHMLKUMI-UHFFFAOYSA-N 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960001235 gentian violet Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 150000002466 imines Chemical group 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- SQFDQLBYJKFDDO-UHFFFAOYSA-K merbromin Chemical compound [Na+].[Na+].C=12C=C(Br)C(=O)C=C2OC=2C([Hg]O)=C([O-])C(Br)=CC=2C=1C1=CC=CC=C1C([O-])=O SQFDQLBYJKFDDO-UHFFFAOYSA-K 0.000 description 1
- 229940008716 mercurochrome Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses an external anti-inflammatory and bacteriostatic gel spray and a preparation method thereof. The gel spray takes acid polysaccharide Hyaluronic Acid (HA) as a main material, and utilizes carboxyl on a polysaccharide structure of the HA to graft with Polylysine (PLL) rich in an amino structure through amidation reaction to obtain HA-PLL; the main component of catechin, epigallocatechin gallate (EGCG), is synthesized into EGCG dimer through Bayer acid catalytic condensation, and is coupled with hyaluronic acid to obtain HA-EGCG, wherein the EGCG can generate active quinone under physiological conditions due to the structure containing pyrogallol by tyrosinase (SA _ Ty) mediated oxidation, and the generated active quinone can be covalently combined with amino on HA-PLL to form stable hydrogel.
Description
Technical Field
The invention relates to an external composition with an anti-inflammatory effect, in particular to an external anti-inflammatory and bacteriostatic gel spray and a preparation method thereof.
Background
Skin abrasions are a very common type of trauma in everyday life, which is extremely common in sports activities. Skin abrasion refers to damage caused by the friction of a rough foreign object against the epidermis layer of the skin. In addition, skin abrasion may be accompanied by blunt blow, high fall, traffic accidents, and the like.
Improper treatment of abrasions can lead to ulceration and suppuration of the skin. If the foreign matters (such as dust, gravel and the like) in the wound are not completely removed, traumatic tattoos, scars and the like are left after healing, and if the bruises are positioned on the face or joints and the like, the patients can be seriously stressed by influencing the appearance or limiting the movement. Thus, timely treatment of skin abrasions is extremely important for wound healing.
After the bruise happens, the wound needs to be cleaned in time in the first step, and then the medicine is applied and is properly wrapped according to the degree of the wound. The existing external use medicine has various types, and has classical disinfectants such as mercurochrome, gentian violet, iodophor and the like, and also has a spray preparation added with various pain-relieving and inflammation-diminishing medicines. The classic disinfectant is gradually not accepted by the public because the wound is colored and not easy to clean after being coated on the wound, the beauty of the human body is affected and the like. In contrast, spray formulations are more popular with the public due to their ease of use. However, the spray preparation is liable to lose efficacy with water evaporation at the wound, the duration of efficacy is short, multiple continuous administrations are required, and in the case of severe bruising, dressing treatment may be required for preventing bacterial infection after spray treatment, and repeated administration may be required due to the short duration of efficacy, which is a relatively large challenge to patient compliance.
In summary, the conventional scratch treatment has the following disadvantages:
1. the traditional lotion of red and purple colors can seriously color the skin, is not easy to clean and affects the beauty;
2. the spraying preparation has short drug effect time and needs to be sprayed for many times;
3. some traditional bandaging methods, such as woundplasts and gauzes, are easily adhered to the wound due to direct contact with the wound, and easily tear the wound to cause secondary injury when being torn off.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide an external gel spray with the functions of diminishing inflammation and healing wounds and a preparation method thereof.
The purpose of the invention and the technical problem to be solved are realized by adopting the following technical scheme. According to the external anti-inflammatory and bacteriostatic gel spray provided by the invention, two materials of HA-PLL and HA-EGCG are used as main bodies to form stable gel;
the HA-PLL is obtained by grafting acid polysaccharide hyaluronic acid and polylysine;
the HA-EGCG is obtained by synthesizing epigallocatechin gallate dimer through Bayer acid catalytic condensation and coupling with hyaluronic acid.
The invention provides a preparation method of the external anti-inflammatory and bacteriostatic gel spray, which comprises the following steps:
1) Preparation of HA-PLL:
weighing sodium hyaluronate, dissolving in water, adding 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride, adjusting pH, standing, adding N-hydroxysuccinimide, continuously stirring, weighing polylysine, adding into the solution, adjusting pH, reacting, dialyzing the solution, and freeze-drying to obtain HA-PLL;
2) Preparation of HA-EGCG:
dissolving aminoacetaldehyde diethyl acetal in a mixture of cold methane sulfonic acid and tetrahydrofuran; dissolving EGCG in tetrahydrofuran and cold methane sulfonic acid, slowly adding the mixed solution under stirring, and stirring for 12h at room temperature in a dark place; concentrating the obtained mixture by a rotary evaporator for 15-30 min, and vacuum-drying for 24h at room temperature; extracting and purifying the product, and performing rotary evaporation to obtain EGCG dimer;
coupling dimerized EGCG to hyaluronic acid by EDC-NHS chemistry to form HA-EGCG;
3) Preparation of hydrogel:
preparing an HA-PLL aqueous solution; dissolving tyrosinase in the HA-PLL aqueous solution, and marking as a solution A; preparing HA-EGCG aqueous solution, and marking as solution B; and uniformly mixing the solution A and the solution B to form stable gel.
Further, in the preparation method of the external gel spray for anti-inflammation and bacteriostasis, in the step 1), the sodium hyaluronate is dissolved in water, and each 1g of sodium hyaluronate is dissolved in 50mL of water; the mass ratio of the sodium hyaluronate to the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride is 2:0.8 to 1.2; the mass ratio of the sodium hyaluronate to the N-hydroxysuccinimide is as follows: 2:0.8 to 1.2; the mass ratio of the sodium hyaluronate to the polylysine is as follows: 2:0.8 to 1.5.
In a further aspect, in the step 1), the mass ratio of the sodium hyaluronate to the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride is 2:1; the mass ratio of the sodium hyaluronate to the N-hydroxysuccinimide is as follows: 2:1; the mass ratio of the sodium hyaluronate to the polylysine is as follows: 2:1.
further, in the preparation method of the external anti-inflammatory and bacteriostatic gel spray, in the step 1), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride is added, the pH is adjusted to be 5.0-6.0, and the standing time is 15-30 min; adding N-hydroxysuccinimide, and stirring for 15-30 min; the polylysine is weighed and added, the pH is adjusted to 7.4-10.0, and the reaction lasts for 12-24 h.
Furthermore, in the preparation method of the gel spray for external use with anti-inflammatory and antibacterial effects, in the step 1), after the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride is added, the pH is adjusted to 5.5; after the polylysine was added, the pH was adjusted to 8.0.
Further, in the preparation method of the gel spray for external use for anti-inflammation and anti-bacteria, in the step 1), the dialysis is performed for 1 day in a sodium hydroxide solution with pH =10, and then is performed for 3 days in pure water.
Further, in the preparation method of the gel spray for external use with anti-inflammatory and bacteriostatic effects, in the step 2), the volume ratio of the aminoacetaldehyde diethyl acetal to the mixture of the cold methane sulfonic acid and tetrahydrofuran is 29;
in the mixture of the cold methane sulfonic acid and the tetrahydrofuran, the volume ratio of the cold methane sulfonic acid to the tetrahydrofuran is 1:5;
the EGCG dissolution ratio is 0.8-1.2 g/mL, and the volume ratio of tetrahydrofuran to cold methane sulfonic acid is 1500-3000: 1;
the extraction is to dissolve the product in 10mL of pure water and extract and purify the product for 5 to 10 times by using 10mL of ethyl acetate;
the coupling of dimerised EGCG to hyaluronic acid comprises the steps of: weighing hyaluronic acid, dissolving the hyaluronic acid in pure water, adding excessive 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride, standing for 15-30 min, then adding N-hydroxysuccinimide with the same molar amount as the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride, continuously stirring for 15-30 min, adding EGCG dimer, stirring for reacting for 12-18 h, dialyzing the product, and freeze-drying to obtain HA-EGCG;
still further, in the above method for preparing a gel spray for external use for anti-inflammation and anti-bacteria, the dimerized EGCG is coupled to hyaluronic acid, and the sodium hyaluronate is dissolved in water at a ratio of 50mL per 1g of sodium hyaluronate; the mass ratio of the sodium hyaluronate to the EGCG dimer is 2; the dialysis is performed by dialyzing the product against a dialysis membrane in pure water for 3 days.
Further, in the preparation method of the external anti-inflammatory and bacteriostatic gel spray, in the step 3), the preparation concentration of the HA-PLL aqueous solution is 0.1g/mL; the preparation concentration of tyrosinase in the solution A is 1mg/mL; the preparation concentration of the HA-EGCG aqueous solution is 0.04-0.1 g/mL; the solution A and the solution B are mixed according to a volume ratio of 1.
Furthermore, in the preparation method of the external gel spray for anti-inflammation and bacteriostasis, in the step 3), the preparation concentration of the HA-EGCG aqueous solution is 0.08g/mL.
By means of the technical scheme, the invention at least has the following advantages:
1) HA-PLL is rich in amino, can react with active quinone to generate crosslinking, and meanwhile, PLL is a natural biological metabolic product and HAs good bactericidal capacity;
2) EGCG in the HA-EGCG HAs good antioxidant activity, generates active quinone under the catalysis of tyrosinase, can be adhered to tissues while being crosslinked with HA-PLL, prevents the invasion of bacteria, and avoids the direct contact between a binding material and a wound;
3) The hydrogel disclosed by the invention has better biocompatibility, oxidation resistance and antibacterial activity, can provide good physiological conditions for wound healing, has good adhesion performance, can be adhered to the skin in a longer time period, and can play a role in isolating foreign matters such as bacteria while avoiding repeated administration.
Drawings
FIG. 1 is a schematic representation of example 5 before and after forming a gel;
FIG. 2 shows the results of the biocompatibility test of the hydrogels of the examples.
Detailed Description
The gel spray takes acid polysaccharide Hyaluronic Acid (HA) as a main material, and utilizes carboxyl on a polysaccharide structure of the HA-HA to graft (graft through covalent bonds) with Polylysine (PLL) rich in an amino structure through amidation reaction to obtain HA-PLL; the main component of catechin, epigallocatechin gallate (EGCG), is synthesized into EGCG dimer through Bayer acid catalytic condensation, and is coupled with hyaluronic acid to obtain HA-EGCG, the EGCG can be oxidized into active quinone due to the structure containing pyrogallol, which is similar to melanin chemistry and mussel induced adhesion chemistry, and the EGCG can generate active quinone under physiological conditions through tyrosinase (SA _ Ty) mediated oxidation, and HAs no cytotoxicity.
The preparation method of the hydrogel material with the function of promoting bone repair comprises the following steps:
1) Preparation of polylysine grafted hyaluronic acid (HA-PLL)
Weighing 2g of sodium hyaluronate (molecular weight of 100000) and dissolving in 100mL of water, adding 1g of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDC) after dissolving, adjusting the pH to 5.5, activating carboxyl groups on the hyaluronic acid, adding 1g of N-hydroxysuccinimide (NHS) after 15min, continuing stirring for 15min, weighing 1g of PLL and adding into the solution, adjusting the pH to 8.0, reacting overnight, filling the solution into a dialysis bag (molecular weight cut-off: 12-14 kDa), dialyzing in sodium hydroxide solution with pH =10 for 1 day, dialyzing in pure water for 3 days, and freeze-drying to obtain polylysine grafted hyaluronic acid (HA-PLL).
2) Preparation of EGCG grafted hyaluronic acid (HA-EGCG)
mu.L of aminoacetaldehyde diethyl acetal was dissolved in 1.2mL of a mixture of cold methanesulfonic acid (MSA) and Tetrahydrofuran (THF) (1, 5,v/v). EGCG (2.29 g) was dissolved in 3.8mL THF and 1.7. Mu.L MSA, and the above mixed solution was slowly added with stirring and stirred overnight at room temperature in the dark. The resulting mixture was concentrated by rotary evaporator for 20 minutes and dried under vacuum at room temperature overnight. The product is dissolved in 10mL of pure water, extracted and purified by 10mL of ethyl acetate for about 5-10 times, and rotary evaporated to obtain EGCG dimer.
Next, dimerized EGCG was coupled to hyaluronic acid by EDC-NHS chemistry to form EGCG grafted hyaluronic acid (HA-EGCG): weighing 1g of hyaluronic acid, dissolving the hyaluronic acid in 50mL of pure water, adding excessive EDC, activating carboxyl for 15min, then adding NHS with the same molar amount as EDC, continuing stirring for 15min, adding 0.5g of EGCG dimer, stirring for reacting for 6h, dialyzing the mixture in pure water for 3 days by using a dialysis membrane (12-14 kDa), and freeze-drying to obtain HA-EGCG.
The scheme takes two materials of HA-PLL and HA-EGCG as main bodies, the HA-EGCG generates active quinone under the catalysis of tyrosinase (SA _ Ty), the active quinone can react with amino on the HA-PLL to generate an imine structure to generate crosslinking, the active quinone can also combine with groups on wound tissues to play a certain adhesion performance, and a formed gel layer can effectively isolate the invasion of bacteria so as to accelerate the healing of wounds.
The hydrogel disclosed by the invention has better biocompatibility, oxidation resistance and antibacterial activity, can provide good physiological conditions for wound healing, has good adhesion performance, can be adhered to the skin in a longer time period, and can play a role in isolating foreign matters such as bacteria while avoiding repeated administration.
Example 1
As an example of the gel spray with wound healing promotion function of the present invention, the present example includes the following components in the following concentrations: 0.05g/mLHA-PLL, 0.02g/mL HA-EGCG, 0.5mg/mL tyrosinase.
The hydrogel described in this example includes the following steps:
1. preparing an HA-PLL aqueous solution with the concentration of 0.1g/mL;
2. dissolving tyrosinase in the HA-PLL solution, and preparing a solution A with the concentration of 1mg/mL;
3. preparing 0.04g/mL HA-EGCG aqueous solution, and marking as solution B;
4. and uniformly mixing the solution A and the solution B according to a volume ratio of 1.
Example 2
As an example of the gel spray with wound healing promotion function of the present invention, the present example includes the following components in the following concentrations: 0.05g/mL HA-PLL, 0.025g/mL HA-EGCG, 0.5mg/mL tyrosinase.
The hydrogel described in this example includes the following steps:
1. preparing an HA-PLL aqueous solution with the concentration of 0.1g/mL;
2. dissolving tyrosinase in the HA-PLL solution, and preparing a solution A with the concentration of 1mg/mL;
3. preparing 0.05g/mL HA-EGCG aqueous solution, and marking as solution B;
4. and uniformly mixing the solution A and the solution B according to a volume ratio of 1.
Example 3
As an example of the gel spray with wound healing promotion function of the present invention, the present example includes the following components in the following concentrations: 0.05g/mL HA-PLL, 0.03g/mL HA-EGCG, 0.5mg/mL tyrosinase.
The hydrogel of the embodiment comprises the following steps:
1. preparing an HA-PLL aqueous solution with the concentration of 0.1g/mL;
2. dissolving tyrosinase in the HA-PLL solution, and preparing a solution A with the concentration of 1mg/mL;
3. preparing 0.06g/mL HA-EGCG aqueous solution, and marking as solution B;
4. and uniformly mixing the solution A and the solution B according to a volume ratio of 1.
Example 4
As an example of the gel spray with wound healing promotion function according to the present invention, the present example includes the following components in the following concentrations: 0.05g/mL HA-PLL, 0.035g/mL HA-EGCG, 0.5mg/mL tyrosinase.
The hydrogel of the embodiment comprises the following steps:
1. preparing an HA-PLL aqueous solution with the concentration of 0.1g/mL;
2. dissolving tyrosinase in the HA-PLL solution, and preparing solution A with the concentration of 1mg/mL;
3. preparing 0.07g/mL HA-EGCG aqueous solution, and marking as solution B;
4. and uniformly mixing the solution A and the solution B according to a volume ratio of 1.
Example 5
As an example of the gel spray with wound healing promotion function according to the present invention, the present example includes the following components in the following concentrations: 0.05g/mL HA-PLL, 0.04g/mL HA-EGCG, 0.5mg/mL tyrosinase.
The hydrogel described in this example includes the following steps:
1. preparing an HA-PLL aqueous solution with the concentration of 0.1g/mL;
2. dissolving tyrosinase in the HA-PLL solution, and preparing a solution A with the concentration of 1mg/mL;
3. preparing 0.08g/mL HA-EGCG aqueous solution, and marking as solution B;
4. and uniformly mixing the solution A and the solution B according to a volume ratio of 1.
Schematic diagrams before and after the glue is formed in the embodiment are shown in fig. 1.
Example 6
As an example of the gel spray with wound healing promotion function of the present invention, the present example includes the following components in the following concentrations: 0.05g/mL HA-PLL, 0.045g/mL HA-EGCG, 0.5mg/mL tyrosinase.
The hydrogel described in this example includes the following steps:
1. preparing an HA-PLL aqueous solution with the concentration of 0.1g/mL;
2. dissolving tyrosinase in the HA-PLL solution, and preparing a solution A with the concentration of 1mg/mL;
3. preparing 0.09g/mL HA-EGCG aqueous solution, and marking as solution B;
4. and uniformly mixing the solution A and the solution B according to a volume ratio of 1.
Example 7
As an example of the gel spray with wound healing promotion function of the present invention, the present example includes the following components in the following concentrations: 0.05g/mL HA-PLL, 0.05g/mL HA-EGCG, 0.5mg/mL tyrosinase.
The hydrogel of the embodiment comprises the following steps:
1. preparing an HA-PLL aqueous solution with the concentration of 0.1g/mL;
2. dissolving tyrosinase in the HA-PLL solution, and preparing a solution A with the concentration of 1mg/mL;
3. preparing 0.1g/mL HA-EGCG aqueous solution, and marking as solution B;
4. and uniformly mixing the solution A and the solution B according to a volume ratio of 1.
Eg. comparative example
Preparation of hydrogel:
1. preparing an HA-PLL aqueous solution with the concentration of 0.1g/mL; marking as a solution A;
2. preparing 0.08g/mL HA-EGCG aqueous solution, and marking as solution B;
3. and uniformly mixing the solution A and the solution B according to a volume ratio of 1.
Eg. comparative example
Preparation of hydrogel:
preparing 0.08g/mL HA-EGCG aqueous solution, adding tyrosinase to prepare 1mg/mL HA-EGCG aqueous solution; a stable gel was formed.
Eg. comparative example 1
Preparation of polylysine-grafted hyaluronic acid (HA-PLL):
weighing 2g of sodium hyaluronate (molecular weight of 100000) and dissolving in 100mL of water, adding 1g of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDC) after dissolving, adjusting the pH to 5.5, activating carboxyl groups on the hyaluronic acid, adding 1g of N-hydroxysuccinimide (NHS) after 15min, continuing stirring for 15min, weighing 1g of PLL and adding into the solution, adjusting the pH to 8.0, reacting overnight, filling the solution into a dialysis bag (molecular weight cut-off: 12-14 kDa), dialyzing in sodium hydroxide solution with the pH =10 for 1 day, dialyzing in pure water for 3 days, and freeze-drying to obtain polylysine grafted hyaluronic acid (HA-PLL).
Preparation of EGCG grafted hyaluronic acid (HA-EGCG):
coupling EGCG to hyaluronic acid by EDC-NHS chemistry to form EGCG grafted hyaluronic acid (HA-EGCG): weighing 1g of hyaluronic acid, dissolving the hyaluronic acid in 50mL of pure water, adding excessive EDC, activating carboxyl for 15min, then adding NHS with the molar quantity equal to that of EDC, continuing stirring for 15min, adding 0.5g of EGCG, stirring for reacting for 6h, dialyzing the mixture in pure water for 3 days by using a dialysis membrane (12-14 kDa), and freeze-drying to obtain HA-EGCG.
Preparation of hydrogel:
1. preparing an HA-PLL aqueous solution with the concentration of 0.1g/mL;
2. dissolving tyrosinase in the HA-PLL solution, and preparing a solution A with the concentration of 1mg/mL;
3. preparing 0.08g/mL HA-EGCG aqueous solution, and marking as solution B;
4. and uniformly mixing the solution A and the solution B according to a volume ratio of 1.
Eg. comparative example 2
Preparation of polylysine-grafted hyaluronic acid (HA-PLL):
weighing 2g of sodium hyaluronate (molecular weight 100000) and dissolving in 100mL of water, adding 1g of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDC) after dissolving, adjusting the pH to 5.5, activating carboxyl on hyaluronic acid, adding 1g of N-hydroxysuccinimide (NHS) after 15min, continuously stirring for 15min, weighing 1g of PLL and adding into the solution, adjusting the pH to 8.0, reacting overnight, filling the solution into a dialysis bag (molecular weight cut-off: 12-14 kDa), dialyzing in sodium hydroxide solution with the pH =10 for 1 day, dialyzing in pure water for 3 days, and freeze-drying to obtain polylysine grafted hyaluronic acid (HA-PLL).
Preparation of hydrogel:
1. preparing an HA-PLL aqueous solution with the concentration of 0.1g/mL;
2. dissolving tyrosinase in the HA-PLL solution, and preparing a solution A with the concentration of 1mg/mL;
3. preparing 0.08g/mL EGCG aqueous solution, and marking as solution B;
4. the solution A and the solution B are uniformly mixed according to the volume ratio of 1, and the method cannot form gel.
Pure EGCG HAs a relatively small molecular weight, can react with HA-PLL after being oxidized by tyrosine, but cannot form a cross-linked network, and finally can exist in a flocculent precipitate form, so that gel cannot be formed.
Eg. comparative example 3
Preparation of polylysine-grafted hyaluronic acid (HA-PLL):
weighing 2g of sodium hyaluronate (molecular weight of 100000) and dissolving in 100mL of water, adding 1g of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDC) after dissolving, adjusting the pH to 5.5, activating carboxyl groups on the hyaluronic acid, adding 1g of N-hydroxysuccinimide (NHS) after 15min, continuing stirring for 15min, weighing 1g of PLL and adding into the solution, adjusting the pH to 8.0, reacting overnight, filling the solution into a dialysis bag (molecular weight cut-off: 12-14 kDa), dialyzing in sodium hydroxide solution with the pH =10 for 1 day, dialyzing in pure water for 3 days, and freeze-drying to obtain polylysine grafted hyaluronic acid (HA-PLL).
Preparation of hydrogel: preparing an HA-PLL aqueous solution with the concentration of 0.1g/mL; tyrosinase was dissolved in the above HA-PLL solution, and this method failed to gel.
Example of Effect verification
1. Hydrogel gel formation time test
Testing the gel forming time of the hydrogel by adopting an inversion method, uniformly mixing the solution A and the solution B, pouring the mixture into a glass bottle, repeatedly inverting the glass bottle until the mixed solution does not flow any more, and recording the gel forming time of the hydrogel.
Table 1 shows the results of the gel-forming time tests of the examples, from which it can be seen that when the concentration of HA-PLL is fixed, the gel-forming time decreases with increasing concentration of HA-EGCG, since the proportion of EGCG is also higher in high concentrations of HA-EGCG, which increases in proportion and rate of oxidation to active quinone under the catalysis of tyrosinase, thereby accelerating the crosslinking and formation of gel. The gelling time of example 5 is 38.73 +/-8.36 s, and the quick gelling characteristic makes the gel spray prepared.
TABLE 1 gel formation time for the examples
2. Adhesion test
Cutting fresh pigskin into small pieces with the length multiplied by 1cm, scraping off a fat layer, cleaning, wiping off excessive water by using gauze, uniformly coating a thin layer of hydrogel liquid on the 2 multiplied by 1cm part of the center of one pigskin (marked as P1), slightly covering one end of the other pigskin (marked as P2) on an area containing the hydrogel liquid, placing the pigskin in a refrigerator at 4 ℃, taking out the pigskin after 30min, fixing the pigskin P1 on a universal mechanical tester platform, clamping the other end of the pigskin P2 by using a clamp, performing tensile stripping at an angle of 90 degrees with the angle of P2, recording the change of force along with the stripping length in the stripping process, integrating the curve of the force and the stripping length, and calculating the average stripping strength.
The results of the tack test for each example are shown in table 2 below.
TABLE 2 tack test results for each example
As can be seen from table 2, the viscosity of the hydrogel increases with the increase of the concentration of HA-EGCG, because the proportion of EGCG increases, and the pyrogallol can be combined with some surface groups on skin tissues through chemical bonding and intermolecular force while participating in gelling after being oxidized into active quinone, so as to present a certain adhesiveness.
3. Test for Oxidation resistance
By the use of H 2 O 2 Detection kit for detecting hydrogen peroxide (H) 2 O 2 ) The concentration was decreased to evaluate the antioxidant capacity of the hydrogel. First, H is established within a suitable concentration range 2 O 2 Standard Curve, adding 100. Mu.L of hydrogel to 1mL of H 2 O 2 In solution (25 mM). After 30min of reaction, the remaining H was determined 2 O 2 And (4) concentration.
The damaged part is often accompanied by the rise of Reactive Oxygen Species (ROS), the ischemia injury caused by the ROS rise causes the obvious increase of proinflammatory cytokines such as TNF-alpha and IL-6, thereby causing the inflammation infiltration of ischemic tissues, and the gel clearance activity is tested forOxygen capacity, tested by the present invention against H 2 O 2 The results of the antioxidant performance test of each example are as follows
Shown in table 3.
TABLE 3 antioxidant Performance test results of the examples
As can be seen from Table 3, the active oxygen scavenging capacity of the gel is enhanced along with the increase of the HA-EGCG ratio, and the appropriate HA-EGCG concentration can effectively relieve the inflammatory symptoms at the wound and accelerate the healing of the wound.
4. Antibacterial property
The antibacterial performance of the hydrogel was evaluated with gram-positive staphylococcus aureus and gram-negative escherichia coli. The OD value of the bacteria in the antibacterial test was adjusted to 0.1. Co-culturing the hydrogel sample and the bacterial suspension in a biochemical incubator at 37 ℃, and measuring the OD value of the blended bacterial liquid after 12 hours.
100 μ L of the bacterial suspension was diluted and plated on LB agar plates. The number of culturable colonies was counted after 24h incubation at 37 ℃ using the following formula:
AR(％)＝(Nc-Ns)/Nc×100；
the Antibacterial Ratio (AR) was calculated, where Nc is the average number of colonies of the control sample and Ns is the average number of bacterial colonies of the hydrogel sample.
The results of the in vitro antibacterial testing for each example are shown in table 4 below.
TABLE 4 in vitro antibacterial test results for each example
As seen from table 4, the hydrogel exhibited better antibacterial properties because the antibacterial properties of the gel were reduced when the concentration of HA-EGCG was increased to a certain degree due to the presence of PLL in the gel, which may be that a part of amino groups in HA-PLL were bonded, thereby decreasing the antibacterial properties of the gel.
5. Biocompatibility
Cultured human dermal fibroblasts were digested with 0.25% trypsin and suspended at a density of 2X 10 per well 4 one/mL cell suspension was seeded in 48-well plates. Culturing for 12 hr, taking out stock culture solution, transferring hydrogel sample to 48-well plate, inoculating 10-contained hydrogel 5 Cell suspension 100. Mu.L/mL. Each group is provided with at least 5 holes. The liquid is changed every 24h, and three time points of 1d, 4d and 7d are set in the experiment. The specific operation method comprises the following steps:
cell survival rate: cell viability was quantified using CCK 8. The corresponding well plate was removed at the indicated time intervals, 100. Mu.L of CCK8 working solution was added to each well, and carbon dioxide incubator (containing 5% CO) was maintained at a constant temperature of 37 ℃ 2 ) After incubation for 1-2 h, measuring the absorbance (OD) at the wavelength of 450nm by using an enzyme-labeling instrument, and calculating the cell survival rate according to the formula:
cell survival (%) = OD experimental group/OD control group × 100%.
Fig. 2 shows the result of the biocompatibility test of the hydrogel of each example, and it can be seen from fig. 2 that when the concentration of HA-EGCG is lower, the gel shows weak toxicity, which may be due to more residual amino groups remaining in the gel, and the biocompatibility of the gel shows a certain gain effect as the proportion of HA-EGCG increases, which indicates that HA-PLL and HA-EGCG in proper proportion are almost non-toxic to human cells, which provides an advantage for using the hydrogel as a gel spray.
The above description is only a preferred embodiment of the present invention, and is not intended to limit the present invention in any way, so that any simple modification, equivalent change and modification made to the above embodiment according to the technical spirit of the present invention are within the scope of the technical solution of the present invention.
Claims (10)
1. An external gel spray for anti-inflammation and bacteriostasis, which is characterized in that: two materials of HA-PLL and HA-EGCG are used as main bodies to form stable gel;
the HA-PLL is obtained by grafting acid polysaccharide hyaluronic acid and polylysine;
the HA-EGCG is obtained by synthesizing epigallocatechin gallate dimer through Bayer acid catalytic condensation and coupling with hyaluronic acid.
2. The preparation method of the gel spray for external use with anti-inflammation and bacteriostasis is characterized by comprising the following steps:
1) Preparation of HA-PLL:
weighing sodium hyaluronate, dissolving in water, adding 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride, adjusting pH, standing, adding N-hydroxysuccinimide, continuously stirring, weighing polylysine, adding into the solution, adjusting pH, reacting, dialyzing the solution, and freeze-drying to obtain HA-PLL;
2) Preparation of HA-EGCG:
dissolving aminoacetaldehyde diethyl acetal in a mixture of cold methane sulfonic acid and tetrahydrofuran; dissolving EGCG in tetrahydrofuran and cold methanesulfonic acid, slowly adding the mixture of the cold methanesulfonic acid and the tetrahydrofuran in which aminoacetaldehyde diethyl acetal is dissolved under stirring, and stirring for 12 hours at room temperature in a dark place; concentrating the obtained mixture by a rotary evaporator for 15-30 min, and vacuum-drying for 24h at room temperature; extracting and purifying the product, and performing rotary evaporation to obtain EGCG dimer;
coupling dimerized EGCG to hyaluronic acid by EDC-NHS chemistry to form HA-EGCG;
3) Preparation of hydrogel:
preparing an HA-PLL aqueous solution; dissolving tyrosinase in the HA-PLL aqueous solution to obtain a solution A; preparing HA-EGCG aqueous solution, and marking as solution B; and uniformly mixing the solution A and the solution B to form stable gel.
3. The method of claim 2, wherein: in the step 1), the sodium hyaluronate is dissolved in 50mL of water per 1g of sodium hyaluronate;
the mass ratio of the sodium hyaluronate to the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride is 2:0.8 to 1.2;
the mass ratio of the sodium hyaluronate to the N-hydroxysuccinimide is as follows: 2:0.8 to 1.2;
the mass ratio of the sodium hyaluronate to the polylysine is as follows: 2:0.8 to 1.5.
4. The production method according to claim 3, characterized in that: in the step 1), the mass ratio of the sodium hyaluronate to the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride is 2:1;
the mass ratio of the sodium hyaluronate to the N-hydroxysuccinimide is as follows: 2:1;
the mass ratio of the sodium hyaluronate to the polylysine is as follows: 2:1.
5. the method of claim 2, wherein: in the step 1), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride is added, the pH is adjusted to be 5.0-6.0, and the standing time is 15-30 min;
adding N-hydroxysuccinimide, and stirring for 15-30 min;
the polylysine is weighed and added, the pH value is adjusted to 7.4-10.0, and the reaction time is 12-24 h.
6. The method of claim 5, wherein: in the step 1), after the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride is added, the pH is adjusted to 5.5;
after the polylysine was added, the pH was adjusted to 8.0.
7. The method of claim 2, wherein: in the step 1), the dialysis is performed for 1 day in a sodium hydroxide solution with pH =10, and then for 3 days in pure water.
8. The production method according to claim 2, characterized in that: in the step 2), the volume ratio of the aminoacetaldehyde diethyl acetal to the cold methane sulfonic acid and tetrahydrofuran mixture is 29;
in the mixture of the cold methane sulfonic acid and the tetrahydrofuran, the volume ratio of the cold methane sulfonic acid to the tetrahydrofuran is 1:5;
the EGCG dissolution ratio is 0.8-1.2 g/mL, and the volume ratio of tetrahydrofuran to cold methane sulfonic acid is 1500-3000: 1;
the extraction is to dissolve the product in 10mL of pure water and extract and purify the product for 5 to 10 times by using 10mL of ethyl acetate;
the coupling of dimerized EGCG to hyaluronic acid comprises the steps of: weighing hyaluronic acid, dissolving the hyaluronic acid in pure water, adding excessive 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride, standing for 15-30 min, adding N-hydroxysuccinimide with the same molar amount as the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride, continuously stirring for 15-30 min, adding EGCG dimer, stirring for 12-18 h, dialyzing the product, and freeze-drying to obtain HA-EGCG;
coupling the dimerized EGCG to hyaluronic acid, said sodium hyaluronate dissolved in water being dissolved in 50mL of water per 1g of sodium hyaluronate; the mass ratio of the sodium hyaluronate to the EGCG dimer is 2; the dialysis is performed by dialyzing the product against a dialysis membrane in pure water for 3 days.
9. The method of claim 2, wherein the HA-PLL aqueous solution is prepared at a concentration of 0.1g/mL in step 3);
the preparation concentration of tyrosinase in the solution A is 1mg/mL;
the preparation concentration of the HA-EGCG aqueous solution is 0.04-0.1 g/mL;
the solution A and the solution B are mixed according to a volume ratio of 1.
10. The method for preparing the compound of claim 9, wherein the HA-EGCG aqueous solution is prepared at a concentration of 0.08g/mL in the step 3).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211331456.7A CN115957178A (en) | 2022-10-28 | 2022-10-28 | External anti-inflammatory and bacteriostatic gel spray and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211331456.7A CN115957178A (en) | 2022-10-28 | 2022-10-28 | External anti-inflammatory and bacteriostatic gel spray and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115957178A true CN115957178A (en) | 2023-04-14 |
Family
ID=87357756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211331456.7A Pending CN115957178A (en) | 2022-10-28 | 2022-10-28 | External anti-inflammatory and bacteriostatic gel spray and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115957178A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090142309A1 (en) * | 2003-01-10 | 2009-06-04 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
| CN106902392A (en) * | 2017-03-01 | 2017-06-30 | 西南交通大学 | Carry the preparation method of heparin/poly-D-lysine nano-particle hyaluronic acid gel |
| CN111732741A (en) * | 2020-06-24 | 2020-10-02 | 华熙生物科技股份有限公司 | Method for crosslinking hyaluronic acid and polylysine, composite crosslinked product obtained by method and application of composite crosslinked product |
| CN112190763A (en) * | 2020-06-15 | 2021-01-08 | 南京工业大学 | Hyaluronic acid/epsilon-polylysine antibacterial hydrogel and preparation method and application thereof |
| CN112778772A (en) * | 2020-12-31 | 2021-05-11 | 中山大学附属第一医院 | Antibacterial composite hydrogel and preparation method and application thereof |
| CN113559314A (en) * | 2021-08-06 | 2021-10-29 | 西北大学 | Extracellular matrix-simulated hydrogel dressing for diabetic foot ulcer and preparation method thereof |
-
2022
- 2022-10-28 CN CN202211331456.7A patent/CN115957178A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090142309A1 (en) * | 2003-01-10 | 2009-06-04 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
| CN106902392A (en) * | 2017-03-01 | 2017-06-30 | 西南交通大学 | Carry the preparation method of heparin/poly-D-lysine nano-particle hyaluronic acid gel |
| CN112190763A (en) * | 2020-06-15 | 2021-01-08 | 南京工业大学 | Hyaluronic acid/epsilon-polylysine antibacterial hydrogel and preparation method and application thereof |
| CN111732741A (en) * | 2020-06-24 | 2020-10-02 | 华熙生物科技股份有限公司 | Method for crosslinking hyaluronic acid and polylysine, composite crosslinked product obtained by method and application of composite crosslinked product |
| CN112778772A (en) * | 2020-12-31 | 2021-05-11 | 中山大学附属第一医院 | Antibacterial composite hydrogel and preparation method and application thereof |
| CN113559314A (en) * | 2021-08-06 | 2021-10-29 | 西北大学 | Extracellular matrix-simulated hydrogel dressing for diabetic foot ulcer and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mehrabani et al. | Preparation of biocompatible and biodegradable silk fibroin/chitin/silver nanoparticles 3D scaffolds as a bandage for antimicrobial wound dressing | |
| Zhang et al. | Mussel-inspired antibacterial polydopamine/chitosan/temperature-responsive hydrogels for rapid hemostasis | |
| CN112316204B (en) | Metal polyphenol collagen membrane material, preparation method and application thereof | |
| Luo et al. | Thermogelling chitosan-based polymers for the treatment of oral mucosa ulcers | |
| CN110314242B (en) | Preparation method and application of controlled-release antibiotic composite hydrogel | |
| CN104399082A (en) | Nutrient gel for sterilizing and healing wound surface and preparation method of nutrient gel | |
| Wei et al. | Facile preparation of polyphenol-crosslinked chitosan-based hydrogels for cutaneous wound repair | |
| Wei et al. | EGCG-crosslinked carboxymethyl chitosan-based hydrogels with inherent desired functions for full-thickness skin wound healing | |
| Huang et al. | Preparation of novel stable microbicidal hydrogel films as potential wound dressing | |
| Bankoti et al. | Dual functionalized injectable hybrid extracellular matrix hydrogel for burn wounds | |
| Cui et al. | A chitosan-based self-healing hydrogel for accelerating infected wound healing | |
| CN110859989B (en) | Liquid band-aid and preparation method thereof | |
| Wei et al. | Honokiol@ PF127 crosslinked hyaluronate-based hydrogel for promoting wound healing by regulating macrophage polarization | |
| Xu et al. | A distinctive nanocomposite hydrogel integrated platform for the healing of wound after the resection of melanoma | |
| CN104784103B (en) | Based on oligomeric amino acid amphiphile, amphiphilic molecule injectable anti-bacterial hydrogel | |
| Al-Musawi et al. | Electrospun Polyvinylpyrrolidone/Soy protein nanofibers enriched with curcumin-loaded ZIF-8 nanoparticles: Synthesis and evaluation for wound healing application | |
| CN104740141B (en) | A kind of antimicrobial spray and preparation method thereof | |
| Wei et al. | Enzymatic one-pot preparation of carboxylmethyl chitosan-based hydrogel with inherent antioxidant and antibacterial properties for accelerating wound healing | |
| Qiao et al. | Host defense peptide-mimicking peptide polymer-based antibacterial hydrogel enables efficient healing of MRSA-infected wounds | |
| CN112891615B (en) | Liquid adhesive bandage and preparation method thereof | |
| Sanjarnia et al. | Nanocomposite chitosan dressing incorporating polydopamine‑copper Janus nanoparticle | |
| CN113509591A (en) | Antibacterial cationic injectable hydrogel dressing and preparation method thereof | |
| CN115957178A (en) | External anti-inflammatory and bacteriostatic gel spray and preparation method thereof | |
| CN111632188A (en) | Seaweed polysaccharide composite biological matrix dressing and preparation method thereof | |
| CN115737887A (en) | Skin wound dressing and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20230414 |
|
| RJ01 | Rejection of invention patent application after publication |